Cargando…
塞瑞替尼450 mg随餐服用治疗中国ALK阳性非小细胞肺癌患者的安全性及近期疗效分析
BACKGROUND AND OBJECTIVE: Anaplastic lymphoma kinase (ALK) rearrangement is a common driver gene of non-small cell lung cancer (NSCLC). Ceritinib is a second-generation ALK inhibitor, which can bring survival benefits to ALK-positive metastatic NSCLC. However, few studies focus on the safety and eff...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467981/ https://www.ncbi.nlm.nih.gov/pubmed/32838488 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.33 |